A phase II GETNE-DUTHY trial evaluating durvalumab plus tremelimumab reported findings in advanced thyroid carcinoma, aiming to expand immunotherapy options for a cancer type with limited effective strategies in advanced settings. The trial was led by Capdevila, Hernando, Molina-Cerillo, and colleagues and tested the combination of the PD-L1 inhibitor durvalumab with the CTLA-4 inhibitor tremelimumab. Although details are limited in the provided source, the program positions dual checkpoint blockade as a candidate approach for improving outcomes in advanced thyroid cancer. For oncologists, the key near-term question will be whether the regimen delivers durable responses without unacceptable toxicity in the studied population.